Site Editor

William J. Gradishar, MD, FACP, FASCO


Aditya Bardia, MD, MPH, on Clinical Implications of Using Datopotamab Deruxtecan vs Chemotherapy for Advanced Breast Cancer

Posted: Thursday, January 11, 2024

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses practical issues surrounding the use of datopotamab deruxtecan, an antibody-drug conjugate that seems to improve progression-free survival compared with chemotherapy in previously treated patients with inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.